J. Cadranel

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

Filippo de Marinis, Tae Min Kim, L. Bonanno et al. · Annals of Oncology · 2025 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16

[Practices of transcutaneous liver biopsies in France. Results of a retrospective nationwide study].

J. Cadranel, Pierre Rufat, Françoise Degos · PubMed · 2001 · 19 citations

Medicine, Pathology, Hepatology +9

[Nodular regenerative hyperplasia associated with primary antiphospholipid syndrome].

J. Cadranel, R Demontis, Catherine Guettier et al. · PubMed · 1996 · 15 citations

Medicine, Pathobiology, Neoplasia +6

2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi

M-J. Ahn, T.M. Kim, L. Bonanno et al. · Journal of Thoracic Oncology · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +6

Retrospective investigation of patients exposed to possible transmission of hepatitis C virus by a capillary blood glucose meter

Z. Kadi, P. Saint-Laurent, J. Cadranel et al. · Journal of Hospital Infection · 2006 · 10 citations

Medicine, Infectious Diseases, Internal Medicine +10